Nuvalent, Inc. Segments Disclosure
11. Segment Information
The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2018. The Company’s operations are organized and reported as one reportable segment, which includes all activities related to the discovery, development, and commercialization of precisely targeted therapies for patients with cancer. This presentation is consistent with how the Company’s chief operating decision maker (“CODM”), its , assesses the performance of the Company and makes operating decisions on a consolidated basis. The accounting policies of the consolidated segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on consolidated net loss as reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total assets. The Company’s assets are held in the United States.
The following table sets forth the Company’s segment information (in thousands):
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Direct external expenses by program: |
|
|
|
|
|
|
|
|
|
|||
Zidesamtinib |
|
$ |
59,519 |
|
|
$ |
62,110 |
|
|
$ |
27,878 |
|
Neladalkib |
|
|
105,446 |
|
|
|
67,778 |
|
|
|
31,894 |
|
NVL-330 |
|
|
21,819 |
|
|
|
8,293 |
|
|
|
10,634 |
|
Discovery programs |
|
|
11,875 |
|
|
|
9,178 |
|
|
|
8,586 |
|
Personnel-related expenses |
|
|
73,163 |
|
|
|
44,121 |
|
|
|
29,225 |
|
Stock-based compensation expense |
|
|
86,502 |
|
|
|
60,579 |
|
|
|
25,563 |
|
General and administrative professional and consultant fees |
|
|
15,033 |
|
|
|
10,854 |
|
|
|
6,423 |
|
Change in fair value of related party revenue share liability |
|
|
55,220 |
|
|
|
17,940 |
|
|
|
— |
|
Interest income |
|
|
(44,794 |
) |
|
|
(38,372 |
) |
|
|
(23,277 |
) |
Other segment items(1) |
|
|
41,009 |
|
|
|
17,511 |
|
|
|
9,293 |
|
Income tax provision |
|
|
585 |
|
|
|
764 |
|
|
|
— |
|
Consolidated net loss |
|
$ |
(425,377 |
) |
|
$ |
(260,756 |
) |
|
$ |
(126,219 |
) |
(1) Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.